肝细胞癌：治疗指南与医学治疗
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment.
作者信息
Kudo Masatoshi, Trevisani Franco, Abou-Alfa Ghassan K, Rimassa Lorenza
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, OsakaSayama, Japan.
Semeiotic Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
出版信息
Liver Cancer. 2016 Nov;6(1):16-26. doi: 10.1159/000449343. Epub 2016 Nov 29.
Abstract
Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have many commonalities but may also differ in certain aspects, as described in this article. In view of the limited therapeutic options for advanced HCC, evidence-based therapies are few, and thus there is a dependence on consensus-based guidelines. This article focuses on the Italian Association for the Study of the Liver guidelines and the Japanese approaches to therapy, while drawing attention to certain controversies from other academic bodies where applicable and appropriate.
摘要
本文所述，西方和东方对于肝细胞癌（HCC）治疗指南的观点有许多共性，但在某些方面也可能存在差异。鉴于晚期HCC的治疗选择有限，基于证据的疗法较少，因此依赖基于共识的指南。本文重点关注意大利肝脏研究协会的指南和日本的治疗方法，同时在适用和适当的情况下，提请注意其他学术机构的某些争议。
相似文献
1
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment.
Liver Cancer. 2016 Nov;6(1):16-26. doi: 10.1159/000449343. Epub 2016 Nov 29.
2
Hepatocellular carcinoma surveillance: Eastern and Western perspectives.
Ultrasonography. 2019 Jul;38(3):191-199. doi: 10.14366/usg.18043. Epub 2018 Oct 28.
3
Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Oncology. 2011;81 Suppl 1:158-64. doi: 10.1159/000333280. Epub 2011 Dec 22.
4
Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma.
World J Gastroenterol. 2023 Dec 21;29(47):6122-6137. doi: 10.3748/wjg.v29.i47.6122.
5
Systematic evidence-based clinical practice guidelines are ushering in a new stage of standardized management of hepatocellular carcinoma in Japan.
Drug Discov Ther. 2014 Apr;8(2):64-70. doi: 10.5582/ddt.8.64.
6
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part I - Surgical treatments.
Dig Liver Dis. 2024 Feb;56(2):223-234. doi: 10.1016/j.dld.2023.10.029. Epub 2023 Nov 28.
7
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.
Dig Dis. 2011;29(3):339-64. doi: 10.1159/000327577. Epub 2011 Aug 9.
8
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
9
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part II - Non-surgical treatments.
Dig Liver Dis. 2024 Mar;56(3):394-405. doi: 10.1016/j.dld.2023.10.028. Epub 2023 Dec 4.
10
Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia.
Int J Surg. 2022 Jun;102:106094. doi: 10.1016/j.ijsu.2021.106094. Epub 2022 Jun 1.
引用本文的文献
1
Exploration Biomarkers for Recurrence of Hepatocellular Carcinoma After Liver Transplantation Based on Bioinformatics Analysis.
Biochem Genet. 2025 Aug 18. doi: 10.1007/s10528-025-11227-8.
2
Recent advancement in the anticancer efficacy of the natural flavonoid scutellarin: a comprehensive review.
Front Pharmacol. 2025 Mar 27;16:1579609. doi: 10.3389/fphar.2025.1579609. eCollection 2025.
3
A transformer-based deep learning survival prediction model and an explainable XGBoost anti-PD-1/PD-L1 outcome prediction model based on the cGAS-STING-centered pathways in hepatocellular carcinoma.
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbae686.
4
Performance of contrast-enhanced ultrasound liver imaging reporting and data system for differentiation of patients at risk of hepatocellular carcinoma and liver metastasis.
Ann Med. 2025 Dec;57(1):2442072. doi: 10.1080/07853890.2024.2442072. Epub 2024 Dec 19.
5
Intravoxel incoherent motion and enhanced T2*-weighted angiography for preoperative prediction of microvascular invasion in hepatocellular carcinoma.
Front Oncol. 2024 Aug 9;14:1389769. doi: 10.3389/fonc.2024.1389769. eCollection 2024.
6
miR‑576‑3p/M‑phase phosphoprotein 8 axis regulates the malignant progression of hepatocellular carcinoma cells via the PI3K/Akt signaling pathway.
Oncol Lett. 2024 May 16;28(1):327. doi: 10.3892/ol.2024.14460. eCollection 2024 Jul.
7
Prevalence, patterns, risk factors and outcomes of peritoneal metastases after laparoscopic hepatectomy for hepatocellular carcinoma: a multicenter study from China.
Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):3-15. doi: 10.21037/hbsn-22-506. Epub 2023 Jun 8.
8
A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma.
iScience. 2024 Jan 4;27(2):108797. doi: 10.1016/j.isci.2024.108797. eCollection 2024 Feb 16.
9
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.
Hepatol Int. 2024 Feb;18(1):4-31. doi: 10.1007/s12072-023-10599-6. Epub 2023 Oct 21.
10
Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Clin J Gastroenterol. 2023 Dec;16(6):793-802. doi: 10.1007/s12328-023-01860-4. Epub 2023 Sep 23.
本文引用的文献
1
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.
Hepat Oncol. 2014 Apr;1(2):181-188. doi: 10.2217/hep.14.3. Epub 2014 Jan 29.
2
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.
3
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.
Liver Cancer. 2014 Oct;3(3-4):458-68. doi: 10.1159/000343875.
4
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.
5
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).
Hepatol Res. 2015 Jan;45(2). doi: 10.1111/hepr.12464.
6
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Invest New Drugs. 2015 Feb;33(1):159-68. doi: 10.1007/s10637-014-0167-5. Epub 2014 Oct 8.
7
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
JAMA. 2014 Jul 2;312(1):57-67. doi: 10.1001/jama.2014.7189.
8
How to define transarterial chemoembolization failure or refractoriness: a European perspective.
Liver Cancer. 2014 May;3(2):119-24. doi: 10.1159/000343867.
9
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Int J Clin Pract. 2014 May;68(5):609-17. doi: 10.1111/ijcp.12352. Epub 2013 Nov 28.
10
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.
Liver Cancer. 2012 Sep;1(2):62-70. doi: 10.1159/000342402.
Zotero 插件